Full Report - Research for Development - Department for ...

Chinayon
(1998)
(+)/(+)
Kamilya
(2005)
(-)/(-)
Naz (2005)
(++)/(++)
Women with
eclampsia
Women with
eclampsia
Women with
eclampsia
Revised administration of magnesium
sulphate
Liberalisation of Caesarean section
New guidelines to promote routine use of
magnesium sulphate
Use of magnesium sulphate as
anticonvulsant in management of eclampsia
cases.
Neonatal
mortality
Perinatal
mortality
Maternal
mortality
Stillbirth
Perinatal
mortality
Maternal
mortality
Maternal
mortality
Appendix 4.1
A retrospective review of 90 eclamptic
patients between 1987 and 1996 found
three maternal deaths (3.3%). Perinatal
deaths and neonatal deaths were 9 and
5 out of 75 (cases of eclampsia before
pregnancy) respectively. The authors
conclude that magnesium sulphate
should be used routinely for eclampsia
patients, ideally with intravenous
loading dose followed by intramuscular
injections.
From 1995 – 1997, the case fatality rate
of eclampsia fell from 11.3% to 5.3%.
The perinatal mortality also fell from
54.8% to 24.3%. The Caesarean section
rate for eclampsia increased from near
10% to 49.7%.
There was no comparison group to
assess the effectiveness of magnesium
sulphate. From observational data, the
authors believed it to be an effective
anticonvulsant in control and
prophylaxis of seizures. There were 4
maternal deaths from eclampsia from 52
patients admitted.
What are the effects of different models of delivery for improving maternal and infant health outcomes for poor people in urban areas in low income
and lower middle income countries?
197